The Middle East and Africa systemic aspergillosis and systemic candidasis market is projected to reach US$ 231.76 million by 2027 from US$ 184.03 million in 2019; it is estimated to grow at a CAGR of 3.0% from 2020 to 2027. The growth of the systemic aspergillosis and systemic candidasis market is primarily attributed to rise in prevalence of fungal diseases and hospital acquired fungal infections. Moreover, the COVID-19 pandemic has highly affected countries in Middle East and Africa, further affecting the systemic aspergillosis and systemic candidasis market in the region.
Systemic aspergillosis and systemic candidasis are the types of fungal infections. Molds cause the aspergillosis infection and majorly affects the respiratory tract of an individual. In addition, it is a severe pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable leading to death, severe chronic illness, or blindness. For instance, Candida Auris's emergence is considered one of the most severe problems associated with nosocomial transmission and infection control practices in the hospital environment. Moreover, as per data published by the Global Action Fund for the Fungal Infection in 2018, about 213 million people are affected by severe fungal disease infections in Ghana, South Africa, Ethiopia, and Taiwan. Moreover, as per the study, in South Africa, an expected 99,350 cases of pulmonary aspergillosis (CPA) which estimated to rate of about 175/100,000. In Ghana, it is estimated 12,620 patients at an estimated 44/100,000, and a similar rate of prevalence to Uganda and Bangladesh estimated to 46/100,000 and 41/100,000 respectively.
In 2019, the systemic oral-azoles accounted for the highest share and is expected to grow faster during the forecast period as due to its advancementin systemic antifungal therapy. For instance, fluconazole has the most attractive pharmacologic (pharmacokinetics and pharmacodynamic) profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid and urine.
A few major primary and secondary sources associated with this report on the systemic aspergillosis and systemic candidasis market are, the US Food and Drug Administration (FDA), National Library of Medicine National Institutes of Health, and Centers for Disease Control and Preventions.